Compare Charles River Laboratories Intl. Inc (CRL) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Shell PLC — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Shell PLC trades at $90.53 (market cap $250.44B). The key difference: Shell PLC is far larger — about 18.6× Charles River Laboratories Intl. Inc's market cap, and Shell PLC pays a 3.45% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | SHEL | |
|---|---|---|
Market Cap | $13.46B | $250.44B |
Sector | Health | Energy |
52-Week High | $282.00 | $94.15 |
52-Week Low | $145.57 | $70.31 |
Enterprise Value | $16.30B | $292.14B |
Dividend Yield | — | 3.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
SHEL trades at $90.12, up 0.19% today, with a bullish technical signal from moving averages and strong Q2 2026 earnings beating estimates. The stock shows attractive valuation metrics with a P/E of 10.01 and P/S of 0.88, supported by a 14.35% ROE and 8.76% net income margin. Recent news highlights oil price gains boosting energy stocks and Shell's strategic divestments, such as selling its European renewables unit to TotalEnergies.
Outlook remains positive due to discounted valuation, rising cash flow, and analyst consensus favoring buys with a $103.60 price target. Key risks include commodity price volatility, regulatory pressures, and execution challenges in energy transitions. The stock offers value with upside potential but requires monitoring of oil market dynamics and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
